Abeona therapeutics announces presentation on new preclinical data supporting the potential of cre-mediated dual aav vector technology to enable delivery of large genes targeted for treatment of stargardt disease at arvo 2021 annual meeting

New york and cleveland, april 20, 2021 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo), a fully-integrated leader in gene and cell therapy, today announced that new data from its preclinical research will be highlighted during an oral presentation at the association for research in vision and ophthalmology (arvo) 2021 annual meeting, being held virtually from may 1-7, 2021.
ABEO Ratings Summary
ABEO Quant Ranking